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Tobacco smoking and alcohol consumption as 
risk factors for thymoma – A European case-
control study 
Mikael Eriksson, Linda Kaerlev, Preben Johansen, Noemia Afonso, Wolfgang Ahrens, Altamiro 
Costa-Pereira, Pascal Guénel, Karl-Heinz Jöckel, Agustin Llopis Gonzalez, Franco Merletti, Maria 
Morales Suárez-Varela, Brigitte Trétarre, Gun Wingren, Lorenzo Richiardi, Svend Sabroe.  
Abstract 
Purpose 
Hardly anything is known about the aetiology of thymoma. This paper presents data regarding 
tobacco smoking and alcohol consumption in relation to thymoma from the first case-control study 
performed on this rare tumour. 
Methods 
A European multi-centre case-control study including incident cases aged 35–69 years with 
thymoma between 1995 and 1997, was conducted in seven countries. A set of controls, used in 
seven parallel case-control studies by the same research group was used, including population-
based controls from five countries and hospital controls with colon cancer from two countries. 
Altogether 103 cases, accepted by a reference pathologist, 712 colon cancer controls, and 2071 
population controls were interviewed. 
Results 
Tobacco smoking was moderately related with thymoma (OR 1.4, 95% CI 0.9–2.2), and a tendency 
to dose-response was shown (p = 0.04), with an increased risk for heavy smokers defined as ≥41 
pack-years (OR 2.1, 95% CI 1.1–3.9). A high consumption of spirits defined as ≥25 g of alcohol per 
day was associated with an increased risk of thymoma (OR 2.4, 95% CI 1.1–5.4), whereas no 
association was found with beer or wine. 
Conclusions 
Tobacco smoking and a high intake of spirits were indicated as risk factors for thymoma. 
1. Introduction 
Thymomas are rare tumours originating from thymic epithelial cells, i.e. from the thymus. 
Thymomas are most often encapsulated benign tumours, but must always be regarded as potentially 
malignant with possibility of invasiveness, metastatic spread and recurrences. The most common 
site for metastases is pleura. Some of them are obviously well differentiated carcinomas. The WHO 
classification separates five categories: medullary, lymphocyte-rich, cortical, mixed, and well 
differentiated thymic carcinomas [1,2]. The incidence of thymoma in Europe and in the USA is 
approximately 0.1-0.3 per 100 000 in males and females. Most cases occur between 40 and 60 years 
of age [3,4]. Thymus is an important part of the immune system, and there is a well-known 
association between thymoma and autoimmune disease, especially myasthenia gravis, recently 
iterated in a study of 85 cases of thymoma [5]. However, thymoma is considered as the causal 
factor of these disorders, with disappearing of symptoms if the tumour is operated. 
Very little is known about the aetiology of thymoma. EBV infection has been reported as a suspect 
risk factor for thymic carcinomas in some studies as reviewed by Sweeney et al. [3], also including 
reports that the EBV genome is present in thymomas occurring in Chinese patients. A Japanese 
report describes a case of suspected causal relationship between HTLV-1 carrier state and thymoma 
[6]. Furthermore, a case of thymoma among 49 different tumours in a group of patients with HIV 
infection is reported from Italy [7]. In a register study from England and Wales, not separating 
thymomas from thymic carcinomas, a birth cohort analysis showed the lowest risk for persons born 
during the Second World War [8]. Irradiation may be of etiologic interest shown by some reports of 
synchronous thyroid and thymic malignancy following childhood irradiation [9]. Very few papers 
report anything about chemical exposures and thymoma. Animal studies have shown that vinyl 
carbamate may induce thymomas if administered in the first weeks after birth [10]. One case report 
describes a case of thymoma in a worker exposed to fluorocarbons in an automobile plant [11]. A 
case series from France with 37 patients with thymic carcinoma showed that half of them (19/37) 
were smokers, indicating tobacco as a possible risk factor [12]. 
Since very little is known about risk factors, we performed the first case-control study on this 
disease, focusing upon life-style factors and occupational exposures. In this paper we present data 
regarding tobacco and alcohol consumption in relation to thymoma. 
2. Material and methods 
This study was a part of a large multi-centre case-control project conducted in ten European 
countries and including seven different rare tumours, among them thymoma, using a large common 
control group for all the different tumour sites. The project, which has been described in detail in 
earlier reports [[13], [14], [15], [16]], aimed at including enough cases of the rare tumours 
investigated by a multi-national effort. 
In the thymoma study, cases and controls from the following regions in seven countries were 
included: Denmark (the whole country); Sweden (Umeå, Örebro/Uppsala, Linköping, Lund); 
France (Calvados, Côte d´Or, Doubs, Hérault, Isère, Manche, Bas-Rhin, Haut-Rhin, Somme, Tarn); 
Germany (Hamburg, Bremen, Essen, Saarland), Italy (Torino, Firenze, Padova); Spain 
(Valencia/Navarra, Pais Vasco); Portugal (Lisboa, Porto). The population of the participating 
regions of these countries are approximately five million, five million, six million, four million, 
three million, six million and four million, respectively. Cases of thymoma were also recruited in 
Latvia and Lithuania, but it was not possible to obtain a sufficient recruitment of cases in these 
countries, and thus these cases and their corresponding controls were excluded from the analyses. 
Incident cases of thymoma in patients aged 35–69 years in these regions were included in a two-
year period during 1995–1997, with the exact time somewhat differing between the countries 
participating [15]. Thus, only newly diagnosed cases were included, no prevalent cases. Case 
inclusion was ascertained through repeated requests to hospital and pathology departments and/or 
by frequent screening of cancer and pathology registers. We only included areas where we 
considered it possible to get a very good coverage of new cases, but of course single cases may 
have been missed. 
All epithelial tumours of thymic origin were included in this study. All histologically verified cases 
with topography code C37.9 according to ICD-O 1990, and with morphology code 8580/0-8580/3, 
were accepted for a centralised pathological review [17]. One reference pathologist (PJ), blinded 
with respect to exposure status, reviewed a representative HE-stained histological slide together 
with the report from the local pathology department for all cases. The purpose of review was to 
secure a uniform morphologic assessment. The reviewed material, often only one HE-stained 
section, did not allow discrimination between a benign versus a malignant tumour. All cases 
accepted as “definite” were epithelial thymic tumours. Cases accepted as “possible” were either 
cases where the slide showed carcinoma, but origin from the thymus could not be proved, or cases 
with a pathology report classified as “definite” or “possible” with respect to the likeliness of 
thymoma, where sections were not available. Cases not fulfilling these criteria were excluded. 
Population controls were randomly selected from population registers or electoral rolls except for 
Spain and Portugal, where hospital controls with a diagnosis of adenocarcinoma of the colon were 
used. The controls were frequency matched with all cancer cases selected in the seven parallel case-
control studies, within five years age strata by sex and region. The goal was to select at least four 
times as many controls as the number of the most common tumour type in each stratum, and this 
was performed by random selection every three to six months during the study period through the 
case inclusion period. Since the control groups for all seven cancer types were pooled for the 
analyses of each cancer type to obtain the best possible precision, a control-case ratio much higher 
than four was obtained in the thymoma study. This was particularly true for men since two of the 
other rare cancers studied (gall bladder and breast cancer) were restricted to men. For the same 
reasons the control group included a larger proportion of younger subjects reflecting the pooling of 
controls selected for seven different rare cancers of which some were more frequent among the 
younger population than was the case for thymoma. In Spain and Portugal, hospital controls with a 
diagnosis of adenocarcinoma of the colon were selected from the same hospitals as the cases, and 
matched for age and sex. If the index person was dead or too ill to participate, next-of-kin was 
interviewed if possible [18]. 
2.1. Exposure assessment 
All reported incident cases and all selected controls were approached by mail or telephone, and all 
who agreed were contacted further. To collect exposure data, interviews were done by specially 
trained interviewers, face-to-face or by telephone, by means of a highly structured questionnaire. 
This was developed in co-operation between the different centres, originally written in English and 
then translated to the different national languages (Danish, Swedish, French, German, Italian, 
Spanish, Portuguese). The questionnaires included information on socioeconomic and demographic 
status, life style factors, reproductive and medical history and a detailed occupational history. 
Questions on lifestyle addressed tobacco smoking and alcohol consumption. Regarding smoking, all 
subjects were questioned regarding status as current smoker, ex-smoker or never-smoker. A person 
who quitted smoking within the same age or minus one year of age compared to the age at time of 
interview was regarded as a current smoker, since disease related factors could have influenced the 
quitting for that person. Thus, if interviewed at the age of 50 the subject must have quitted smoking 
by the age of 48 or earlier to be regarded as an ex-smoker. Smoking history was expressed as the 
cumulative amount of smoking (‘pack-years’ = number of years as a smoker x number of cigarettes 
per day/20). The quantity for current smokers was based on the consumption five years ago, 
whereas for ex-smokers the consumption at the time they were smoking was typically asked for. 
One cigar was counted as equivalent to five g of tobacco. For hand-rolled cigarettes, cigars, and 
pipe tobacco, 1 g of tobacco was counted as equivalent to one cigarette. Questions on alcohol 
consumption asked for the average daily intake of specific types of alcohol five years before the 
interview. The total daily alcohol intake was computed from the average alcohol content per litre of 
each beverage: beer, 40 g; wine, 94 g; aperitif, 145 g; liquor, 317 g. Since alcohol habits differ 
substantially between countries, e.g., vine versus beer predominance, we also analysed alcohol per 
country. 
2.2. Statistical methods 
Adjusted odds ratios (ORs) were obtained by unconditional logistic regression analysis. All models 
included country (seven categories), year of birth, sex and in the alcohol analyses also tobacco 
smoking status (two categories). Year of birth was used as a continuous variable [19]. Further 
adjustment for level of education (two categories) as a proxy of social status, alcohol consumption 
and body mass index (BMI) (both variables as three categories), as well as a more detailed 
adjustment for region, did not change the ORs and these adjustments were not included in any of 
the final models [20]. 
We used 0–24 g alcohol (corresponding to two drinks) per day as the reference level for total 
alcohol intake, because non-drinkers were few and differ from the population at large in Europe 
with respect to other factors (e.g. lifestyle and social factors). For analyses of trend we introduced 
continuous exposure variables into the models. Due to the small numbers in Table 4 we repeated the 
analyses using an exact test for stratified analyses (StatXact). This method only allowed for 
stratification by country (seven levels), year of birth (three levels), and sex. These additional 
analyses did not change the results significantly, and thus, we have only presented the results from 
the unconditional logistic regression models. Re-running all the analyses with the exclusion of the 
colon cancer controls, together with the Spanish and Portuguese cases, did not change these 
estimates by 10% or more (data not shown). 
The study was approved by the Ethic Committees in each of the participating countries or regions. 
3. Results 
In total, 120 thymoma cases were recruited from seven countries (Sweden, Denmark, France, 
Germany, Italy, Spain, and Portugal), Table 1. Five of these cases (4%), however, were judged as 
not eligible by the reviewing pathologist and were excluded from analyses. Of the 115 remaining 
cases, 93 were classified as "definite" and 22 as "possible". In the latter category the main part, 12, 
were cases with a definite histopathologic report but without any available slide to review because 
of refusal from the local pathologist. In seven cases both the report and slide were regarded as 
possibly thymoma, and in three cases the report indicated that it was possibly a thymoma but the 
slide was not available. 
Table 1. Recruitment of cases with thymoma and controls by country. 
 Cases Controls 
 Identified Pathology review Interviewed Eligible Interviewed 
 N Definite 1 
Possible 
2 Yes No N Yes No 
Country         
 Denmark3 13 9 2 10 (91%) 1 (9 %) 583 320 (55 %) 263 (45 %) 
 Sweden3 14 14 0 10 (71 %) 4 (29 %) 407 230 (57 %) 177 (43 %) 
 France3 26 19 6 25 (100 %) 0 (0 %) 630 485 (77 %) 145 (23 %) 
 Germany3 11 11 0 11 (100 0 (0 %) 1325 733 (55 %) 592 (45 %) 
 Cases Controls 
 Identified Pathology review Interviewed Eligible Interviewed 
 N Definite 1 
Possible 
2 Yes No N Yes No 
Country         
%) 
 Italy 3 26 21 3 21 (88 %) 3 (12 %) 405 303 (75 %) 102 (25 %) 
 Spain4 20 11 9 19 (95 %) 1 (5 %) 580 579 (99 %) 1 (1 %) 
 Portugal4 10 8 2 7 (70 %) 3 (30 %) 138 133 (96 %) 5 (4 %) 
Total 120 93 (78 %) 22 (18 %) 
103 (90 
%) 
12 (10 
%) 4068 
2783 (68 
%) 
1285 (32 
%) 
1 
Definitely a case according to strict morphological criteria. 
2 
Possibly a case according to strict morphological criteria. 
3 
Population controls. 
4 
Colon cancer controls. 
There was no interview performed in twelve of the 115 included cases. Ten of these refused to 
participate, one could not be found at the given address and one was dead and no next-of-kin to 
interview was found. Of the 103 performed interviews, 99 were done with the patient and four were 
surrogate interviews (spouse 2, child 1, friend 1). The participation rate among cases was 90%, with 
a range between 70% in Portugal to 100% in France and Germany. 
Data on smoking was missing for 10 controls. One person from Spain stopped smoking age 77 but 
was only 64 years old – we assumed he has just stopped. For each of the four types of alcohol 
grams alcohol per day were missing for beer (1 case, 15 controls), wine (1 case, 15 controls), liquor 
(1 case, 16 controls) and aperitifs (1 case, 15 controls). 
A total of 4068 controls were selected and among them the interview with the index person was 
completed for 2688, and with a surrogate person for 95, constituting a total participation of 2783 
(68%) among controls, with a variation from 55% in Denmark and Germany to 99% in Spain, Table 
1. 
The interviews were conducted face-to-face (68%), by telephone (31%) or a combination 
(1%). The mean time from diagnosis to interview for cases was 7.8 months. 
Sociodemographic and physical characteristics of the cases and controls are shown in Table 2. Age 
at the time of interview and maximum body mass index (BMI) did not differ between cases and 
controls. Cases were with a slightly higher frequency married (85% versus 80%), and more cases 
than controls were classified as having low educational status (44% versus 38%). 
Table 2. Sociodemographic and physical characteristics of 103 cases with thymoma and 2783 
controls. 
Characteristics 
Cases Controls 
No. Percentage No. Percentage 
Responders:     
 Gender, male 55 53 1885 68 
 Age at 1.1.1995     
35-49 years 33 32 1010 36 
50-59 years 34 33 810 29 
60-69 years 36 35 963 35 
 Mean age at 1.1.1995, years 54.5 – 53.4 – 
 Age at interview     
35-49 years 29 28 883 32 
50-59 years 34 33 729 26 
60-69 years 40 39 1171 42 
 Mean age at interview, years 56.3 – 55.5 – 
 Surrogate interviews 4 4 95 3 
 Marital status     
Married or living with a partner 87 85 2230 80 
 Educational status     
Low 1 45 44 1054 38 
 Maximum BMI 2, ever had 27.0 – 27.3 – 
Non-responders:     
 Gender, male 6 50 900 70 
 Age at 1.1.1995     
35-49 years 2 17 485 38 
50-59 years 6 50 354 27 
60-69 years 4 33 446 35 
 Mean age at 1.1.1995, years 57.0 – 53.0 – 
1 
Left school at the age of 15 years or earlier, no further education. 
2 
Maximum body mass index ever had (but except the last 12 months before the thymoma). 
There was a tendency to an increased risk for thymoma both among subjects who had ever smoked 
(OR 1.4, 95% CI 0.9–2.2), and among current smokers as defined above (OR 1.5, 95% CI 0.9–2.6), 
Table 3. Subjects who had quitted smoking showed only a slight risk increase. A dose-response 
relationship was suggested regarding total smoking quantity, with an increased risk in the highest 
exposure category (≥41 pack-years) yielding OR 2.1 (95% CI 1.1–3.9), and a significant trend 
(p = 0.04). Total years of smoking >20 without regard to quantity gave an OR 1.6 (95% CI 1.0–2.6). 
We also found that smoking > 10 cigarettes per day five years ago without regard to number of 
years gave an OR 1.6 (95% 1.0–2.7). Sub-analyses of tobacco use before and after adjustment for 
alcohol consumption did not change the size of the OR for smoking as a risk factor for thymoma. 
Table 3. Odds ratio (OR) and 95% confidence interval (95% CI) for thymomas according to 
smoking habits, results from a multivariate logistic regressions analysis. 
Smoking 1  Cases Controls Adjusted
2 
OR 95% CI 
  No. No.   
Never smoked tobacco  40 1064 1.0 – 
Ever smoked tobacco  63 1709 1.4 0.9-2.2 
 Current smoker  34 874 1.5 (0.9-2.6) 
 Ex-smoker  29 835 1.3 (0.7-2.2) 
Years of smoking      
 1-20 15 473 1.3 (0.7-2.4) 
 21+ 48 1197 1.6 (1.0-2.6) 
Smoking quantity 5 years ago3      
(cigarettes per day) 1-10 21 568 1.3 (0.8-2.3) 
 11+ 42 1106 1.6 (1.0-2.7) 
Smoking quantity      
(pack-years)4 0 40 1113 1.0 – 
 1 - 20 28 764 1.4 0.8-2.4 
 21 - 40 18 533 1.4 0.8-2.5 
 ≥41 17 373 2.1 1.1-3.9 
1 
Never smokers are used as reference for all odds ratios, except for age at starting smoking 
included in “years of smoking”. Data on smoking was missing for 10 controls. One person 
from Spain stopped smoking age 77 but was only 64 years old – we assumed he has just 
stopped. 
2 
Adjusted for country, age and sex. 
3 
OR for thymoma according to smoking quantity five years before the interview, or when 
smoking for ex-smokers, compared with never smokers. 
4 
Test for trend, p = 0.06. 
Alcohol consumption, when considering beer, spirit and wine combined, did not yield any increased 
risk for thymoma, Table 4. When separated, however, a high intake of spirits (≥ 25 g of alcohol per 
day) was associated with a statistically significant risk, OR 2.4 (95% CI 1.1–5.4), although based on 
few exposed cases in this category. Analysed per country, five out of seven countries show an 
increased risk for this exposure group. No increased risks were seen for beer or wine. 
Table 4. Odds ratio (OR) with 95% confidence (95% CI) intervals for thymoma according to 
drinking habits by country1. 
  All subjects OR (95% CI) 
Alcohol  Cases, N 
Controls, 
N Denmark Sweden France Germany Italy Spain Portugal All 
Alcohol 
total 2 
0 
– 
24 
55 1384 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 
(grams / 
day) 
25 
– 
36 
28 774 1.3 (0.3-5.5) 
0.6 
(0.1-
4.7) 
0.9 
(0.3-
2.4) 
0.8 (0.2-
3.3) 
1.1 
(0.3-
3.7) 
1.1 
(0.4-
3.1) 
5.2 (0.7-
37) 
1.0 
(0.6-
1.7) 
 > 
37 20 625 
1.8 (0.3-
11.9) – 
0.7 
(0.2-
2.4) 
0.4 (0.1-
3.4) 
2.0 
(0.6-
6.6) 
0.7 
(0.2-
3.0) 
1.1 (0.1-
12.7) 
0.9 
(0.5-
1.6) 
Beer 2 0 46 1046 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 
(grams 
alcohol 
/day) 
1 
– 
24 
47 1358 0.4 (0.1-2.0) 
0.8 
(0.2-
3.3) 
1.5 
(0.6-
3.9) 
0.4 (0.1-
1.6) 
1.2 
(0.5-
3.2) 
1.0 
(0.4-
2.7) 
1.6 (0.2-
11.6) 
1.0 
(0.6-
1.5) 
 > 
25 10 379 
1.0 (0.1-
8.1) – 
3.1 
(0.8-
11.6) 
0.3 (0.1-
2.4) – 
0.3 
(0.1-
2.9) 
2.1 (0.2-
23) 
0.9 
(0.4-
1.9) 
Spirit 2 0 43 1080 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 
(grams 
alcohol 
/day) 
1 
– 
24 
52 1604 0.4 (0.1-1.6) 
1.1 
(0.3-
4.6) 
0.8 
(0.3-
1.9) 
0.5 (0.2-
2.0) 
1.0 
(0.4-
2.8) 
1.7 
(0.6-
4.7) 
0.9 (0.1-
6.0) 
0.9 
(0.6-
1.4) 
 > 
25 8 99 – – 
2.0 
(0.2-
18.6) 
3.4 (0.4-
33) 
4.0 
(0.9-
18.7) 
2.1 
(0.2-
19.3) 
5.8 (0.5-
64) 
2.4 
(1.1-
5.4) 
Wine 2 0 29 713 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 
(grams 
alcohol 
/day) 
1 
– 
24 
61 1752 0.5 (0.1-2.4) 
1.2 
(0.2-
6.2) 
0.7 
(0.2-
1.7) 
0.4 (0.1-
1.3) 
1.2 
(0.3-
4.9) 
1.0 
(0.3-
2.9) 
0.8 (0.1-
8.3) 
0.8 
(0.5-
1.2) 
 > 
25 13 318 – – 
0.2 
(0.1-
1.4) 
– 
3.7 
(0.7-
18) 
0.7 
(0.1-
4.2) 
0.7 (0.1-
18) 
0.8 
(0.4-
1.7) 
1 
Adjusted for country, age, sex, and smoking status. 
2 
Missing information on grams alcohol /day for each of the 4 types of alcohol: beer missing 
information for 1 case, 15 controls, wine for 1 case, 15 controls, liquor for 1 case, 16 
controls, aperitifs for 1 case, 15 controls. 
4. Discussion 
To our knowledge, no previous epidemiological studies have been made focusing on potential risk 
factors for thymoma. As a consequence, there are hardly any hypotheses regarding aetiologic 
factors of importance for this tumour. The obvious reasons for this lack of research concern the 
rarity of the disease and the heterogeneous pathology with a range from clearly benign tumours 
through potential malignant thymomas to thymic carcinomas. 
The advantage of this study is the large number of histologically verified incident thymoma cases, 
which has been facilitated by the multi-national co-operation of this project. The participation of 
seven geographically separated European countries, with different climate, traditions and life style, 
made it possible to judge the consistence of our findings regarding risk factors. 
Since the participation rate for the cases (90%) is better than the corresponding rate of 68% for the 
controls, selection bias cannot be ruled out. However, almost no differences were seen regarding 
gender or age between responding and non-responding cases or controls, Table 2. Furthermore, the 
associations found were rather similar in different countries regardless of participation rate. 
Recall bias as a consequence of the use of population controls compared to cases with a tumour 
disease seems not particularly probable since the associations regarding tobacco smoking and spirits 
are not seen for beer or wine. Furthermore, no striking differences are seen between the results in 
Spain and Portugal, using colon cancer controls, compared with the countries using population 
controls. 
Furthermore, in a methodology paper we have described the outcome for colon cancer versus 
population controls in our series of studies on rare cancers, including thymoma [21]. With controls 
frequency matched by gender and 5-year age groups, the colon cancer patients had a higher alcohol 
intake but similar tobacco smoking. This may slightly underestimate the risk for thymoma related to 
alcohol intake, which thus may be somewhat greater than we have found. 
Since no documented risk factors exist for this tumour it is difficult to control for potential 
confounding. 
Tobacco smoking was suggested as a risk factor for thymoma in this study. The association is 
strengthened by the finding of the highest risks in the highest exposure categories regarding years of 
smoking, smoking quantity five years before interview and total smoking quantity ("pack-years"). 
For the latter variable a dose-response tendency was shown. 
Since the thymomas are very rare, there is not a special preventive impact of the findings, but they 
are of scientific interest. A wide variety of epithelial tumours are known to be associated with 
tobacco smoking, e.g., cancer in the lungs, larynx, oesophagus, urinary bladder, kidneys and 
pancreas. Thymomas as well represent tumours with epithelial origin and it is not far-fetched that 
also this kind of tumour may be influenced by the many different carcinogenic substances that are 
identified in tobacco, even if it is difficult to speculate further regarding the closer mechanisms. 
Alcohol consumption overall was not a risk factor for thymoma in this study. However, when only 
considering spirits we found a more than doubled risk for heavy consumers, defined as ≥ 25 g of 
alcohol per day. With the exception of Denmark and Sweden, where no cases were exposed in the 
highest category, all countries showed an increased risk in this respect, which strengthens the 
possibility of a true etiologic association. 
The mechanisms that may explain the finding of a relation between spirits and thymoma are also 
quite unknown. Since no effect was demonstrated by wine or beer, however, some other factor in 
spirits than alcohol may play a role. An unknown confounding factor could also be responsible for 
the finding. Other lifestyle exposures, medical conditions, occupational exposures or a genetic 
susceptibility may as well, in combination with tobacco or spirits, play a role for development of 
thymoma, which may be the focus for further studies [22]. 
Since no other studies so far have been performed on aetiologic factors in thymoma the findings in 
this investigation must be regarded as not more than hypothesis generating. 
In conclusion, this is the first analytical epidemiology study ever published on thymoma, and the 
associations with tobacco smoking and spirit consumption must therefore be interpreted with some 
caution. 
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